Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2024-06-20 00:00:00 ET · period of report 2024-06-18 · accession 0000950170-24-075332 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-20 | 2024-06-18 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +14.4K | 631.2K | +2% | +$30.0K |
| D | 2024-06-20 | 2024-06-18 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $0.00 | -14.4K | 505.6K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-18 | M | A | 14,413 | $2.08 | 631,186 | D | — | — | (F1) This number includes 1,203 shares acquired under the Registrant's employee stock purchase plan on June 1, 2024. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-06-18 | M | D | 14,413 | $0.00 | 505,559 | D | $2.08 · — to 2029-11-13 | 14,413 Common Stock | (F2) The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date. |